Core Viewpoint - A class action has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during a specified period [1][3]. Group 1: Allegations - The complaint states that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient data on chemistry, manufacturing, and controls [3]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [3]. - The delay in regulatory approval raised concerns about the company's need to raise additional capital [3]. Group 2: Impact on Stock Price - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025 [5]. - Shareholders can remain absent class members if they choose not to participate in the case [5].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company misled investors regarding the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][2]. Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information about the differences between its Nanobody drug SLK and traditional monoclonal antibodies, including: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - SLK's Nanobody structure does not provide a clinical benefit over BIMZELX's monoclonal structure [2]. - The supposed increased tissue penetration of SLK does not translate to improved clinical efficacy [2]. - Consequently, the positive statements made by the company regarding SLK's superiority lacked a reasonable basis [2]. Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3]. Next Steps for Investors - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Investors can remain absent class members and still be eligible for recovery without taking any action [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

Core Viewpoint - A class action lawsuit has been filed against WPP PLC, alleging that the company misled investors about its business prospects and financial performance during the specified period [1][2]. Allegations - The complaint claims that WPP PLC created a false impression of having reliable information regarding its projected revenue and growth, while downplaying risks associated with seasonality and macroeconomic factors [2]. - It is alleged that WPP's optimistic reports on client acquisition and retention were misleading, as the company's media division was losing market share and was not competitive [2]. Performance Update - On July 9, 2025, WPP released a trading update indicating a deterioration in performance as the second quarter progressed, attributing this to macroeconomic uncertainties affecting client spending and weaker new business than expected [3]. - Following this announcement, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against WPP PLC, with options to serve as lead plaintiff or remain an absent class member [4]. - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who sold short Marex Group PLC securities, alleging that the company misled investors regarding its financial performance and revenue projections [1][2]. Group 1: Allegations Against Marex Group PLC - The lawsuit claims that Marex Group PLC improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these alleged misrepresentations, class members have reportedly suffered significant losses and damages [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025, to represent the class in the litigation [3]. - Investors do not need to participate actively in the case to be eligible for any potential recovery, and they can remain absent class members if they choose [3]. Group 3: Robbins LLP Overview - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. alleging that the company misled investors regarding its acquisition by Koito Manufacturing Co., Ltd. [1][2] Group 1: Allegations - The lawsuit claims that Cepton did not disclose a credible third-party bid that valued the company at more than double the acquisition price offered by Koito, which was $3.17 per share [3] - It is alleged that Cepton's Board of Directors failed to adequately explore the third-party offer and did not disclose its terms when recommending the Koito acquisition to shareholders [3] - As a result of these actions, shareholders were deprived of the opportunity to make an informed decision regarding the acquisition [3] Group 2: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by December 8, 2025 [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 3: Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - A class action lawsuit has been filed against Fortinet, Inc. for allegedly misrepresenting the impact of unit upgrades of its FortiGate firewalls, leading to significant stock price decline when the truth was revealed [1][2][3]. Group 1: Allegations - The lawsuit claims that Fortinet failed to disclose the difficulty in predicting the total number of FortiGates requiring an upgrade [2]. - It is alleged that customers had excess firewall capacity from previous purchases, reducing the necessity for upgrades [2]. - The complaint states that the refresh of the firewalls had minimal business impact, as it represented only a small percentage of the company's business due to the age of the products [2]. Group 2: Stock Price Impact - Following the revelation of these allegations, Fortinet's stock price dropped over 22%, from $96.58 per share on August 6, 2025, to $75.30 per share on August 7, 2025 [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Fortinet and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly misleading investors about its business prospects during a specific period in 2025 [1][2]. Allegations - The lawsuit claims that PubMatic failed to disclose that a major demand-side platform (DSP) buyer was transitioning clients to a new platform, which affected the evaluation of inventory [2]. - As a result of this transition, PubMatic experienced a decline in advertising spend and revenue from this top DSP buyer [2]. Financial Impact - On August 11, 2025, PubMatic reported its second quarter financial results, indicating a reduction in ad spend from one of its top DSP partners [3]. - CEO Rajeev Goel acknowledged that the shift in inventory evaluation by the DSP buyer created significant challenges for the company [3]. - Following this announcement, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by October 20, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Group 1 - A class action has been filed against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who acquired its securities between May 7, 2025, and August 5, 2025 [1][2] - The allegations include that LifeMD misled investors about its competitive position and failed to properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [2] - Following the announcement of its second quarter 2025 results and a revision of its full-year guidance, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can choose to remain absent class members if they do not wish to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - Semler Scientific is accused of not disclosing an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - The company received an initial civil investigative demand (CID) from the DOJ in July 2017, which investigated whether it violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - On February 11, 2025, Semler Scientific engaged in unsuccessful settlement discussions with the DOJ, raising concerns about a potential lawsuit [3]. Group 2: Financial Impact - Following the revelation of the investigation on February 28, 2025, Semler Scientific's stock price dropped by $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. - After the company announced a settlement agreement with the DOJ for $29.75 million on April 15, 2025, the stock fell by $3.40, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery, and they can remain absent class members if they choose [5].

Group 1 - The core allegation against C3.ai, Inc. is that the company misled investors regarding the impact of its CEO's health on business prospects, specifically in closing deals and executing growth strategies [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to CEO health problems and management reorganization [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share to $16.47 per share, marking a decline of over 25% [2] Group 2 - A class action has been filed on behalf of individuals and entities that purchased C3.ai securities between February 26, 2025, and August 8, 2025, with a deadline for lead plaintiff submissions set for October 21, 2025 [1][3] - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]